Applications of Boc-(R)-3-Amino-4-(2-Chloro-Phenyl)-Butyric Acid in Industrial Manufacturing

Boc-(R)-3-Amino-4-(2-Chloro-Phenyl)-Butyric Acid serves as a critical chiral intermediate in the synthesis pipelines of several downstream industrial sectors. Our production focuses on delivering high-purity material to support consistent manufacturing for regulated applications within fine chemical, pharmaceutical, and specialty molecule synthesis. We highlight the following established industrial scenarios:

1. Chiral Pharmaceutical Intermediate for Antiepileptic Drug Synthesis

This material is widely used as a stereochemically pure building block in the synthesis of next-generation antiepileptic drug APIs, especially within controlled multi-step chiral addition reactions. Manufacturers choose this intermediate for its defined optical purity, which supports the development of CNS-active compounds. Downstream formulation and scale-up require strict traceability and impurity profiling, ensuring the final API meets strict release parameters for human use.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• U.S. FDA cGMP 21 CFR Part 211
• European Pharmacopoeia Monographs (where applicable)
• DMF (Drug Master File) support for regulatory submissions

Typical usage ratio

• 10–25% molar ratio in targeted synthetic steps, with adjustment based on yield optimization and impurity control during API formation

Downstream process integration

• Introduced during the construction of chiral centers within the API core via enantioselective alkylation or amide bond formation steps; subsequent deprotection and purification lead to final active ingredient isolation

Final product types

• Antiepileptic APIs (e.g., Brivaracetam precursor)
• Related chiral intermediates for custom CNS drug research

2. Intermediate for Peptide and Peptidomimetic Synthesis

Peptide manufacturers employ this compound for segment coupling steps when producing protected peptides with modified side chains. Its Boc-protected amino group enables selective deprotection strategies, improving process safety and yield. Use in solid-phase and solution-phase synthesis aligns with high-throughput production needs, reducing racemization risk and ensuring batch consistency for regulated injectable and oral peptide therapeutics.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• European Pharmacopoeia Peptide General Chapters
• U.S. FDA Guidance for Industry: Q5A Viral Safety Evaluation of Biotechnology Products
• ISO 9001 certified manufacturing systems

Typical usage ratio

• Direct coupling at 1:1 stoichiometry with targeted residues; optimization based on protected group choices and total synthesis length

Downstream process integration

• Inserted during peptide elongation or side chain modification, usually as the N-terminal starting fragment or introduced at a defined position for analog generation; final products undergo sequential deprotection and purification

Final product types

• Therapeutic peptides
• Peptidomimetics and peptide APIs
• Diagnostic peptide sequences

3. Fine Chemical Intermediate for Custom Chiral Building Blocks

Custom synthesis labs and advanced material manufacturers utilize this raw material to generate structurally complex, optically active intermediates for specialty chemical applications beyond the pharmaceutical market. Its structural features support synthesis of ligand libraries, novel catalyst scaffolds, and building blocks for advanced polymer or high-value pigment production. Each use case demands rigorous purity and full batch traceability due to the sensitivity of downstream catalytic and polymerization reactions.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• REACH Regulation (EC) No.1907/2006 (for EU chemical registration and use)
• Chemical facility good laboratory practice (GLP) protocols
• Company-specific internal QC specifications aligned to final customer requirements

Typical usage ratio

• 5–15% w/w as a key chiral input, with proportion set per custom synthesis scale and desired enantiomeric excess

Downstream process integration

• Entry as a first or mid-stage intermediate in multi-step synthesis; often employed for asymmetric alkylation or acylation reactions prior to conversion to target functionalized motifs

Final product types

• Chiral ligands for catalysis R&D
• Advanced intermediates for specialty fine chemicals
• Functional monomers and specialty pigments

4. Research Compound for Preclinical Drug Candidate Libraries

Drug discovery groups and CRO/CDMO organizations require high-purity protected chiral amino acids to assemble diverse preclinical compound libraries. This material supports parallel synthesis of analog series for early SAR exploration, enabling route scouting and patentability studies on structurally novel CNS or metabolic candidates. Reliable supply and detailed impurity profiling are essential to support patent filings and IND-enabling studies.

Industry compliance standards

• GLP (Good Laboratory Practice) for preclinical synthesis
• OECD Principles of Good Laboratory Practice
• Internal audit systems for compound tracking in regulated R&D settings
• Material transfer agreements and chain of custody documentation

Typical usage ratio

• Variable, typically 0.5–10 mmol scale per synthetic run, proportional to parallel library size and structural diversification needs

Downstream process integration

• Applied as a protected starting fragment or as a side-chain modification agent during parallel synthesis; scalable for larger hits if advanced to lead optimization

Final product types

• Preclinical research compounds
• SAR and ADME screening libraries
• Advanced hit-to-lead candidates for pharmaceutical development